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Abstract.
BACKGROUND: Persistent infection with high risk human papillomavirus (hrHPV) types causes cervical cancer but most
women who test positive are at very low risk of neoplasia. Strategies are needed which can retain high sensitivity of hrHPV
testing but reduce the number of false-positives. We showed previously that a combination DNA methylation triage assay for
HPV types 16, 18 and 31 and human gene EPB41L3 was useful to identify high grade cervical lesions.
OBJECTIVE: Assess whether measurement of DNA methylation in HPV type 33 can improve the previous classifier.
METHODS: A London colposcopy referral group of 1493 women of whom 556 (37%) had histologically-confirmed CIN (cer-
vical intraepithelial neoplasia) 2 or 3 that included 114 HPV33 positive women with methylation measured for three L2 CpGs
5557, 5560 and 5566. Discrimination performance was assessed for the new classifier S5, built by adding HPV33 to the earlier
classifier.
RESULTS: HPV33 methylation measurement improved prediction among HPV33 positive women. Receiver operating charac-
teristic analyses showed an area under the curve (AUC) for HPV33 methylation of 0.68 (95% CI 0.57–0.78). The earlier risk
score was significantly improved by HPV33 methytlation (AUC = 0.82 vs 0.80; P < 0.001). For 90% sensitivity the specificity
for CIN2/3 was 49% (95% CI 46–52%).
CONCLUSIONS:Measurement of HPV33 DNA methylation contributes independent diagnostic information to EPB41L3 and
HPV16, HPV18 and HPV31, and is superior to genotyping. Other HPV and human methylation target regions might be useful to
further improve S5.
Keywords: Cervical intraepithelial neoplasia, DNA methylation, early detection of cancer, human papillomavirus 33, human
papillomavirus DNA tests, uterine cervical neoplasms
1. Introduction
Pap smear cytological screening has helped save
many womens’ lives [15] despite having only modest
sensitivity for cervical neoplasia and pre-cancerous le-
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sions. Many studies have reported that cytologymisses
more women with high grade cervical intraepthelial
neoplasia (CIN 2/3), for whom treatment may pre-
vent cervical cancer, than testing for high risk hu-
man papilloma virus (hrHPV) types (e.g. [4]). How-
ever, improving on an established, effective and spe-
cific cytology-based screening strategy is not straight-
forward [2]. Most HPV infections clear and so HPV
testing also detects many more women who are not
at risk for CIN2/3. This is part of the reason that in
2011 some organisations in the USA recommended
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cervical screening based on cytology in combination
with hrHPV testing [7]. More recent evidence has sug-
gested that hrHPV testing alone might be used as a pri-
mary screening test, with cytology reserved as a triage
test [21]. An alternative or addition to cytology triage
is a molecular test such as genotyping for HPV16 or
HPV18 that can be performed reflexively from the
original HPV screening specimens. Unfortunately the
positive predictive value of HPV16 and especially of
HPV18 infections is quite low, thus the development of
an improved molecular triage test for hrHPV-positive
women is of potentially huge practical value.
Our long-term objective is to develop a practical
molecular triage test that maintains the high sensitiv-
ity of 14-group cocktail hrHPV testing but with far
fewer false positives, thereby allowing a fully molec-
ular triage test. This would have obvious clinical util-
ity in new automated HPV-based strategies for cervical
screening. An area that has shown some promise for
this objective is the quantitative measurement of DNA
methylation. These epigenetic differences can be accu-
rately measured by molecular methods, and are linked
with the development of a variety of cancers [10]. We
and other research groups have observed that mea-
surement of differential methylation of certain HPV
CpG sites is useful for stratifying HPV type-specific
risk [8,11–13,19]. Additionally, methylation of CpGs
in the promoters or introns of human genes has shown
some value [5,6,9,14,20]. In earlier work we demon-
strated that combining the measurement of human and
HPVmethylationmight produce a better classifier than
either alone [1]. A risk score was developed using
DNA methylation measurement in a group of women
attending for coloposcopy in London, by selecting risk
factors from a large number of potential CpG sites.
The CpGs selected were then assayed on a later cohort
from the same population, for validation andmodel up-
dating. This resulted in a risk score (S4) using DNA
methylation in a human gene EPB41L3, and selected
CpGs in L1 and L2 regions of HPV16, HPV18 and
HPV31. Here, we consider further methylation assays
of HPV33 with an aim to improve S4, and take an-
other step towards a practical molecular test for triage
of hrHPV women in cervical cancer screening.
2. Materials and methods
2.1. Objective
The data that we used in [1] were subsequently
extended, by the assessment of 27 CpG sites in
HPV33 positive women within the same cohorts [19].
The present article focuses on whether HPV33 DNA
methylation testing might add independent triage in-
formation to the previously developed S4 risk score.
That is, the study aims to assess the information
HPV33 methylation levels might add to that from 5
HPV16 CpG sites in L1 and L2 regions, 6 HPV18 L2
sites, 2 HPV31 L1 sites, and 3 CpGs in the human gene
EPB41L3.
2.2. Patients
Data from 1493 hrHPV positive women from the
Predictors 1 (P1) and 2 (P2) studies at St. Mary’s and
Hammersmith Hospitals in Londonwere used to assess
the additional value of HPV33 DNA methylation, with
a focus on increased methylation indicating increasing
risk for CIN2/3. The women had been referred to col-
poscopy because of an abnormal screening cytology
result (persistent borderline or mild, moderate or se-
vere dyskaryosis; equivalent to a diagnosis of atypical
squamous cells of undetermined significance or worse
in the United States of America (USA)). All women
underwent coloposcopic examination, with biopsy and
treatment as appropriate. The studies were approved
by the local research ethics committees and all women
analysed provided written consent and the study con-
forms with The Code of Ethics of the World Medical
Association (Declaration of Helsinki), printed in the
British Medical Journal (18 July 1964); full details are
available elsewhere [17,18].
2.3. Specimen characteristics
Cervical samples were taken prior to colposcopy by
a Cervex brush and placed into PreservCyt (Hologic,
Danbury, USA) and stored at −70◦C until the DNA
methylation assays were run. Details of the DNA ex-
traction and conversion are as previously described [1].
2.4. Assay methods
From the complete P1 and P2 groups, 126 HPV33
samples were selected based on genotyping by the
Linear Array (Roche Molecular Systems, Pleasanton,
USA) and a qPCR test in P1, and the BD HPV test
(BD Diagnostics, Burlington, USA) in P2. The tests
are functionally equivalent to other hrHPV tests [18].
Methylation assays were based on PCR and quanti-
tative pyrosequencing as previously described [1,19].
Primers for 7 PCRs in L2, L1 and URR covering 27
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CpG positions in HPV33 were obtained using Pyro-
Mark Assay Design software version 2.0.1.15 (Qiagen,
Venlo Netherlands), as given in Supplemental Table 3
of [19]. Primers covered dense CpG areas in a single
amplicon of less than 300bp and did not overlap any
CpG dyads. The internal control for total bisulfite con-
version was a non-CpG cytosine in the region for py-
rosequencing.
PCR and pyrosequencing were performed as previ-
ously described [1]. All 27 CpG positions failed for
9/126 samples that were tested for HPV33 methyla-
tion, these were treated as HPV33 negative.
2.5. Primary endpoint and predictor variables
The same subset of hrHPV referral samples from
the P1 (between 2005 and 2007) and P2 (2007–2009)
studies were analysed as used to develop the S4 score
based on HPV16, HPV18, HPV31 and EPB41L3 [1].
This included 114/117 samples from P1 and P2 with
HPV33 methylation data. The primary endpoint was
histologically-confirmed CIN2/3, taking the highest
grade of abnormality seen in the punch or treatment
biopsy specimen. Histopathology was first reported lo-
cally and then centrally reviewed.
Details of the performance and correlation of indi-
vidual HPV33 CpGs were reported earlier [19]. The
analysis identified 6 CpGs in L2 and 3 CpGs in the
L1 regions as being associated with CIN status. For
the present analysis we considered the group of the
best performing CpGs in L2 that may be assessed
with a single primer. These were HPV33 CpGs at
nucleotide positions 5557, 5560, 5566. Mean methy-
lation at these positions was used as the main pre-
dictor variable where zero methylation was imputed
if the measurement failed. For one sample the mea-
surement failed at all three sites, another one failed
at two sites and one sample failed at one site. The
main HPV33 predictor was examined alongside S4,
which used the mean methylation of the CpGs within
a gene or HPV types at nucleotides: EPB41L3: 438,
427, 425; HPV16-L1: 6367, 6389; HPV18-L2: 4256,
4261, 4265, 4269, 4275, 4281; and HPV31-L1: 6352
and 6364 and the proportion of CpGs methylated in
HPV16-L2 sites: 4238, 4259, 4275.
2.6. Statistical analysis methods
Spearman correlation was calculated between
HPV33 methylation and S4. Likelihood ratio chi-
squared statistics from a logistic regression model with
Table 1
Summary statistics for mean methylation at HPV33 CpGs 5557,
5560, 5566
Statistic HPV33
Spearman ρ
S4 (all samples) 0.28 (P = 0.003)
S4 (subset: HPV16,18,31+) 0.22 (P = 0.216)
HPV33+ Methylation
Mean (IQR), <CIN2/3 10% (4–13)
Mean (IQR), CIN2/3 16% (8–21)
P 0.001
When added to S4
Change LR-χ2 50.2
Genotype 43.8 (P < 0.001)
Methylation 6.4 (P = 0.012)
Increase AUC 0.02 (P < 0.001)
terms for S4, HPV33 positivity and HPV33 methyla-
tion were used to assess the benefit of HPV33 methy-
lation. A new rule called Score 5 (S5) was developed
from a logistic regression model with one unknown
parameter for HPV33 and S4 as an offset. The S5
coefficients were rescaled so that the score theoreti-
cally ranged between 0 and 100. Discrimination was
assessed using receiver operating characteristic (ROC)
plots, and the area under the curve (AUC). A sensitivity
analysis was undertaken to assess whether only using
methylation from one HPV type (with preference to (i)
HPV16, (ii) HPV33 and (iii) HPV31) was more predic-
tive than our model assumption of treating multiple in-
fections independently. Comparisons were made to an
HPV genotype rule that ordered risk by positive predic-
tive value in the sample (respectively HPV33, HPV16,
HPV31 and HPV18, as [3]).
Differences between methylation distributions by
CIN status were tested by the Mann-Whitney test. De-
Long confidence intervals were used for AUC statis-
tics, Wilson confidence intervals for binary outcomes
and profile likelihood for logistic regressions. All
P -values were two-sided. Analysis was undertaken by
using the statistical software GNU R 2.15.1 [16].
3. Results
Of 114 HPV33 positive women in the cohort, 71
(62%) had CIN2/3. This HPV33 positive group was
at elevated risk compared with the cohort, where 556/
1493 (37%) had CIN2/3.
Summary statistics are presented in Table 1. HPV33
added significantly to S4 (P < 0.001), where DNA
methylation provided additional information to the
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Fig. 1. ROC plots: (a) HPV33 positive samples and mean HPV33 methylation, (b) all samples and S4, S5, and HPV genotype methylation
positivity ordered by positive predictive value, showing as incremental points (light gray circles) starting at the origin: HPV negative, HPV33,
HPV16, HPV31 and HPV18 respectively. Selected 95% confidence regions at 90% sensitivity cutpoints are also shown (grey +). The difference
between S4 and S5 was significant (P < 0.001).
HPV33 genotype (LR-χ2 6.4, P = 0.012), and
Fig. 1(a) shows how it helped to rank order the risk
of HPV33 positive women (AUC 0.68, 95% CI 0.57–
0.78). Mean HPV33 methylation was moderately cor-
related with the earlier risk score S4 (Spearman 0.28).
A new risk score S5 (score with 1 human gene and
4 HPV types) was estimated as
S5 = 30.9× EPB41L3+ 13.7× HPV16-L1
+4.3× HPV16-L2+ 8.4× HPV18-L2
+22.4× HPV31-L1+ 20.3× HPV33-L1
where HPV33-L2 is the mean of the CpG sites (5557,
5560, 5566) and the other S4 terms were described
above in statistical methods. A sensitivity analysis sup-
ported treating multiple infections independently. A
model that treated HPV types independently fitted the
data much better than one where only the highest-
risk type was used (LR-χ2 = 443.0 vs. 453.9). This
suggested that, for example, when a woman has both
HPV33 and HPV16, it is better for risk prediction to
use the methylation levels in both, than only HPV16.
S4 and S5 were substantially better for risk strat-
ification than genotyping alone (Fig. 1(b)). HPV33
methylation in S5 improved performance over S4 at
the high sensitivity end of the ROC, and because
the S4 components were fixed as previously, the im-
provements were only due to different predictions for
HPV33 positive women. Figure 2 shows the change in
scores, where most of the women had an increased risk
with S5.
The performance of S5 at the 90% sensitivity point
is summarised in Table 2, at this cutpoint specificity
was 49% (95% CI 46–52%) which is superior to the
corresponding specificity of 36% (33–40%) achieved
by S4. A subgroup analysis separating HPV infections
included in the S5 classifier from other high risk HPV
types showed that on the basis of EPB41L3 alone, sen-
sitivity of 49% and specificity of 75% were reached.
4. Discussion
We developed a new risk classifier S5 by expanding
a previously described S4 classifier to include DNA
methylation data from three selected sites in HPV33
L2. The classifier improved the ability to identify high-
grade disease. In the hrHPV positive subgroup with
sensitivity set at 90% for CIN2/3, the specificity of S5
was 49% (95% CI 46–52%). In comparison, the ear-
lier risk score S4 had a specificity of 36% (33–40%),
and the overall improvement in AUC from 0.80 to 0.82
was highly significant [23] (Fig. 1 and Table 1). A
subgroup analysis showed that among the women in-
fected with other hrHPV types than those included in
S5 classifier, only 15% were diagnosed with CIN2/3
and the S5 classifier was able to identify 49% of these.
The lower sensitivity in this subgroup, where detec-
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Table 2
Specificity and positive predictive value (95% CI) from S5 at 90% sensitivity (cutpoint is 0.8)
Group n CIN2/3 (%) Sensitivity Specificity PPV
All samples 1493 556 (37%) 90% (87–92) 49% (46–52) 51% (49–54)
HPV16,18,31,33 935 472 (50%) 97% (96–99) 21% (18–25) 56% (53–59)
Other hrHPV 558 84 (15%) 49% (38–59) 75% (71–79) 26% (22–30)
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Fig. 2. Change in predicted risk for HPV33 positive women for (a) single HPV33 infections and (b) multiple infections with HPV33 and any other
hrHPV type with methylation data (HPV16 or HPV18 or HPV31). The scores have been normalised to show the fitted probability of CIN2/3 for
each HPV33 positive woman in the sample.
tion is based on methylation of EPB41L3 alone, sug-
gested that addition of methylation assays for other
hrHPV may be warranted. Among the 26 human genes
originally considered for the human gene methylation
component of the S4 classifier [22], EPB41L3 showed
the strongest potential. However, the gene selection
was based on earlier reports either describing promis-
ing QMSP assays or showing aberrant methylation by
at least two different research groups. More compre-
hensive ways of identifying novel methylation targets,
such as methylation genome sequencing, are likely to
provide additional human genes that can improve cur-
rent methylation-based classifiers.
HPV33 methylation improved risk stratification
within the HPV33 positive group (Fig. 2) and added
independent information to S4, beyond genotype in-
formation. HPV33 contributed more than twice the in-
formation of HPV18 to risk evaluation (Supplemental
Table S1), and as demonstrated in Fig. 1(b) S5 was a
much stronger risk predictor (AUC = 0.82) than geno-
typing alone (AUC = 0.73, P < 0.001). Our evidence
indicates that that the incremental improvement from
DNA methylation of HPV33 is a real step towards a
clinically useful triage risk score, which is particularly
relevant at a time when hrHPV testing is likely to be-
come the primary screening test [21].
A limitation of our study is that the CpG sites were
selected and evaluated in the same data, and the sam-
ple had a relatively high CIN2/3 prevalence. Thus fur-
ther validation in an independent test set is needed, par-
ticularly in primary screening populations. However,
the study is relatively large, and part of the reason for
fixing the S4 components to be as derived earlier [1]
was to help avoid overfitting. Another limitation is that
the specificity attained for a fixed 90% sensitivity in
a screening population might be different since all the
women in our sample had abnormal cytology. Future
work is planned to assess the performance of S4 and
S5 and appropriate cutpoints for women in a screen-
ing population with a preponderance of normal cytol-
ogy; these women would be detected through primary
hrHPV screening but were not represented in our co-
hort.
In conclusion, quantitative DNA methylation as-
says based on a human gene and hrHPV types show
good promise for the development of molecular tests
to triage hrHPV women to colposcopy in cervical can-
cer screening programs. Furthermore, the S5 classi-
fier is suggested as a possible reflex test to hrHPV
screening not as a replacement. We continue to search
for additional biomarkers that may further improve the
sensitivity and specificity of DNA methylation classi-
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fiers and ultimately design a methylation based test that
could be used in primary screening.
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Supplementary data
Table S1
Univariate and multivariate tests of model components. LR-1 is the
univariate likelihood-ratio χ21; LR-2 is the decrease when dropping
that variable from the full model; LR-3 is the stepwise contribution
in the order of the table so that EPB41L3 is added first because it
is common to all samples, then the HPV predictors are added start-
ing with HPV16 L1. -Log10 P values are given in brackets, where
-Log10 P = 2, 3, 4 if P = 0.01, 0.001, 0.0001 etc. The Spearman
correlation coefficient of each HPV variable with EPB41L3 is also
provided. The overall likelihood ratio χ27 when fitting all terms was
453.86
LR-1 LR-2 LR-3 EPB41L3
Spearman
EPB41L3 152.5 (34.3) 72.4 (16.8) 152.5 (34.3)
HPV16 L1 214.2 (47.8) 63.0 (14.7) 174.7 (39.2) 0.18
HPV16 L2 190.6 (42.6) 33.3 (8.1) 26.2 (6.5) 0.24
HPV31 L1 31.4 (7.7) 40.7 (9.7) 35.6 (8.6) 0.10
HPV18 L2 14.1 (3.8) 20.0 (5.1) 17.8 (4.6) 0.28
HPV33 L1 41.3 (9.9) 47.2 (11.2) 47.2 (11.2) 0.28
